China Sees No Variant Impact On Vaccines, Builds New mRNA Plant
Million Already Inoculated Despite No Final Data
Chinese officials do not expect the new strain of coronavirus emerging in the UK to impact the efficacy of inactivated virus vaccines on the cusp of conditional approval. Meanwhile, a new plant is under construction in China for domestically developed mRNA vaccines.
You may also be interested in...
CanSino's adenovirus-based COVID-19 vaccine, along with another one from state-owned Sinopharm grab promot approvals in China as Beijing shipping millions of doses around the world.
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.